Two ARVO Papers Provide New Insights for Contact Lens-Based Myopia Management with Children
Tuesday, June 23 2020 | 11 h 27 min | Press Release, Vision Science
Two scientific papers being presented as part of the ARVO (Association for Research in Vision and Ophthalmology) 2020 virtual conference proceedings provide eye care professionals (ECPs) with new insights to aid contact lens-based myopia management with children. Both can be accessed from the ARVO Media library catalog within ARVOLearn. Abstracts will be published in Investigative Ophthalmology & Visual Science next month.
ReCSS Study Examines Safety of Pediatric Soft Contact Lens Wear
Robin Chalmers, OD, FAAO, Principal Investigator for the ReCSS study (Retrospective Cohort Study of Safety of Pediatric Soft Contact Lens Wear), led the effort on behalf of CooperVision as part of its FDA approval for MiSight® 1 day contact lenses.* The study retrospectively reviewed 4,611 clinical charts from 782 children across seven geographically and ethnically diverse private eye care practices in the United States and from 181 children in two randomized longitudinal clinical trials.
The record review included any clinical visits of children through age 16 who were first fit with soft contact lenses when 8 to 12 years old. Clinical records involving adverse events were assessed and classified by an independent expert medical panel. The annualized rate of infiltrative adverse events was very low (0.66%/year with a 95% CI 0.39–1.05) as was the annualized rate of contact lens papillary conjunctivitis (0.48%/year with a 95% CI 0.25-0.82). The study estimated a microbial keratitis rate of 7.4/10,000 years (95% CI 1.8–29.6) in soft contact lens wearers aged 8-16 years, comparable to the estimated rates in adult wearers.
Population-Based Centile Analysis Affirms MiSight® 1 day* Contact Lens Clinical Trial Outcomes
Ian Flitcroft, MA, DPhil, FRCOphth, organized a population-based centile analysis of refractive development to assess outcomes from the CooperVision MiSight 1® day contact lens myopia management three-year clinical study in the context of known growth rates of European children. Progression rates for refraction and annual progression were assessed for 113 children participating in the MiSight® 1 day study in Portugal, the United Kingdom and Canada. These were compared to centile calculations for 9,092 Irish children aged 8 to 17, derived from an anonymized sample of optometric health records.
The authors found that treatment led to less progression of myopia than would normally be observed in a standard European optometric practice, and that the control group behaved in the way that would be expected for a typical patient under an ECPs care.
Both studies were supported by grants from CooperVision.
Click HERE for the full press release.
